Clinical Pharmacology & Therapeutics
January 13, 2017
Marilyn A. Huestis, Rachel F. Tyndale
12 citations
This “Designer Drugs 2.0” issue of Clinical Pharmacology & Therapeutics focuses on novel psychoactive substances, primarily cannabinoids and cathinones, and the repurposing of established psychoactive compounds (e.g., modafinil, psilocybin, lysergic acid diethylamide, and 3,4‐methylenedioxymethamphetamine) that simultaneously offer new pharmacotherapies and pose serious health problems. Novel...
Reviews in the Neurosciences
January 1, 2017
Gábor Kapócs, Felix Scholkmann, Vahid Salari et al.
Today, there is an increased interest in research on lysergic acid diethylamide (LSD) because it may offer new opportunities in psychotherapy under controlled settings. The more we know about how a drug works in the brain, the more opportunities there will be to exploit it in medicine. Here, based on our previously published papers and investigations, we suggest that LSD-induced visual...
edoc (University of Basel)
2017
Patrick C. Dolder
1 citation
My PhD thesis consisted of two different scientific parts, each supervised by one of my advisors, Prof. Dr. med. Matthias Liechti and Prof. Dr. sc. nat. Katharina Rentsch. One part was to develop liquid chromatography tandem mass spectrometry (LC-MS/MS) methods to measure d-lysergic acid diethylamide (LSD) and its main metabolites in plasma, serum, and urine samples. We established the...
Current Topics in Behavioral Neurosciences
2017
Juan F López-Giménez, Javier González-Maeso
302 citations
The neuropsychological effects of naturally occurring psychoactive chemicals have been recognized for millennia. Hallucinogens, which include naturally occurring chemicals such as mescaline and psilocybin, as well as synthetic compounds, such as lysergic acid diethylamide (LSD), induce profound alterations of human consciousness, emotion, and cognition. The discovery of the hallucinogenic...